Log in

NASDAQ:KIN - Kindred Biosciences Stock Price, Forecast & News

$9.43
+0.15 (+1.62 %)
(As of 02/16/2020 04:00 PM ET)
Add
Today's Range
$9.21
Now: $9.43
$9.45
50-Day Range
$8.44
MA: $9.34
$10.41
52-Week Range
$5.96
Now: $9.43
$11.35
Volume52,945 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Kindred Biosciences, Inc, a commercial-stage biopharmaceutical company, focusing on developing therapies for pets. Its product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats. It is also developing Zimeta IV and Zimeta Oral for the control of fever in horses. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:KIN
CUSIPN/A
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees146
Next Earnings Date3/4/2020 (Estimated)
OptionableOptionable

Receive KIN News and Ratings via Email

Sign-up to receive the latest news and ratings for KIN and its competitors with MarketBeat's FREE daily newsletter.


Kindred Biosciences (NASDAQ:KIN) Frequently Asked Questions

What is Kindred Biosciences' stock symbol?

Kindred Biosciences trades on the NASDAQ under the ticker symbol "KIN."

How were Kindred Biosciences' earnings last quarter?

Kindred Biosciences Inc (NASDAQ:KIN) issued its quarterly earnings results on Tuesday, November, 12th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing analysts' consensus estimates of ($0.37) by $0.02. The biopharmaceutical company had revenue of $1.10 million for the quarter, compared to analyst estimates of $1.55 million. View Kindred Biosciences' Earnings History.

When is Kindred Biosciences' next earnings date?

Kindred Biosciences is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Kindred Biosciences.

What price target have analysts set for KIN?

8 brokers have issued 12-month price objectives for Kindred Biosciences' stock. Their forecasts range from $8.50 to $25.00. On average, they anticipate Kindred Biosciences' stock price to reach $14.44 in the next twelve months. This suggests a possible upside of 53.1% from the stock's current price. View Analyst Price Targets for Kindred Biosciences.

What is the consensus analysts' recommendation for Kindred Biosciences?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kindred Biosciences in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kindred Biosciences.

Has Kindred Biosciences been receiving favorable news coverage?

Media headlines about KIN stock have trended neutral recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Kindred Biosciences earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Kindred Biosciences.

Are investors shorting Kindred Biosciences?

Kindred Biosciences saw a increase in short interest in January. As of January 31st, there was short interest totalling 753,000 shares, an increase of 16.2% from the January 15th total of 648,200 shares. Based on an average trading volume of 126,400 shares, the short-interest ratio is presently 6.0 days. Approximately 2.1% of the shares of the stock are sold short. View Kindred Biosciences' Current Options Chain.

What other stocks do shareholders of Kindred Biosciences own?

Who are Kindred Biosciences' key executives?

Kindred Biosciences' management team includes the folowing people:
  • Dr. Richard Chin, Co-Founder, CEO & Director (Age 52)
  • Ms. Denise M. Bevers, Co-Founder, Pres, COO, Sec. & Director (Age 52)
  • Ms. Wendy K. Wee, Chief Financial Officer (Age 66)
  • Dr. Hangjun Zhan, Chief Scientific Officer (Age 59)
  • Ms. Katja Buhrer, VP of Corp. Devel. & Investor Relations

Who are Kindred Biosciences' major shareholders?

Kindred Biosciences' stock is owned by many different of institutional and retail investors. Top institutional investors include Ariel Investments LLC (4.56%), Renaissance Technologies LLC (3.02%), State Street Corp (1.79%), UBS Group AG (0.37%), Bank of New York Mellon Corp (0.29%) and Charles Schwab Investment Management Inc. (0.25%). Company insiders that own Kindred Biosciences stock include Park West Asset Management Llc, Raymond Townsend and Richard Chin. View Institutional Ownership Trends for Kindred Biosciences.

Which institutional investors are selling Kindred Biosciences stock?

KIN stock was sold by a variety of institutional investors in the last quarter, including Ariel Investments LLC, Goldman Sachs Group Inc. and Renaissance Technologies LLC. View Insider Buying and Selling for Kindred Biosciences.

Which institutional investors are buying Kindred Biosciences stock?

KIN stock was acquired by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, State Street Corp, Cambridge Investment Research Advisors Inc., Edgewood Management LLC, UBS Group AG, Prudential Financial Inc., Barclays PLC and Banque Cantonale Vaudoise. View Insider Buying and Selling for Kindred Biosciences.

How do I buy shares of Kindred Biosciences?

Shares of KIN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Kindred Biosciences' stock price today?

One share of KIN stock can currently be purchased for approximately $9.43.


MarketBeat Community Rating for Kindred Biosciences (NASDAQ KIN)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  334 (Vote Outperform)
Underperform Votes:  327 (Vote Underperform)
Total Votes:  661
MarketBeat's community ratings are surveys of what our community members think about Kindred Biosciences and other stocks. Vote "Outperform" if you believe KIN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KIN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel